Abliva AB (Nasdaq Stockholm: ABLI) today announces that Magnus Persson is leaving the company's Board of Directors at his own request, to focus on his role as founding Partner at Eir Ventures, a recen ...
On April 22, 2020, the Board of Directors of Abliva AB (publ) ("Abliva" or the "Company") resolved, supported by the authorization granted at the Annual General Meeting on April 25, 2019, on a directe ...
Important events, first quarter (Jan – Mar 2020) NeuroVive proposes a 90 percent guaranteed rights issue of MSEK 74 in order to ensure that the Company has financial resources for […]
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) today announced that the Company's Nomination Committee in its proposal to the Annual General Meeting May 20, 2020, added a proposal regarding an ad ...
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) has prepared a supplementary prospectus (the “Supplementary Prospectus”) to the prospectus that was approved and regi ...
The shareholders of NeuroVive Pharmaceutical AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting, held at 10 a.m. on Wednesday, 20 May 2020 at Medicon V ...
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) has in connection with the forthcoming issue of shares with preferential rights for existing shareholders, announced ...
Today, 17 March 2020, an extraordinary general meeting was held in NeuroVive Pharmaceutical AB (publ) (“NeuroVive” or the “Company”). A summary of the resolutions follows. The resolution was passed wi ...
Important events in 2019 KL1333 NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study NeuroVi ...
Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings".
Read our cookie policy